Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the
diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography
2. To demonstrate that RG1068-enhanced MRCP improves detection and characterization of
intraductal papillary mucinous neoplasms (IPMN) relative to unenhanced MRCP in patients
with suspected IPMN
3. To correlate findings on MRCP with histologically confirmed malignancy